{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,11]],"date-time":"2026-07-11T16:22:20Z","timestamp":1783786940508,"version":"3.55.0"},"reference-count":42,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,1,1]],"date-time":"2019-01-01T00:00:00Z","timestamp":1546300800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,1,1]],"date-time":"2019-01-01T00:00:00Z","timestamp":1546300800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100000009","name":"Foundation for the National Institutes of Health","doi-asserted-by":"publisher","award":["P30CA033572"],"award-info":[{"award-number":["P30CA033572"]}],"id":[{"id":"10.13039\/100000009","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Treatment and Research Communications"],"published-print":{"date-parts":[[2019]]},"DOI":"10.1016\/j.ctarc.2019.100155","type":"journal-article","created":{"date-parts":[[2019,7,3]],"date-time":"2019-07-03T13:03:07Z","timestamp":1562158987000},"page":"100155","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"special_numbering":"C","title":["Randomized trial of oral cyclophosphamide versus oral cyclophosphamide with celecoxib for recurrent epithelial ovarian, fallopian tube, and primary peritoneal cancer"],"prefix":"10.1016","volume":"21","author":[{"given":"Rohan","family":"Gupta","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mihaela","family":"Cristea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Frankel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Ruel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chen","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingyu","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Morgan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucille","family":"Leong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Warren","family":"Chow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marianna","family":"Koczywas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steve","family":"Koehler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dean","family":"Lim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thehang","family":"Luu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cynthia","family":"Martel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"McNamara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George","family":"Somlo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Przemyslaw","family":"Twardowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yun","family":"Yen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amanam","family":"Idorenyi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tinsley","family":"Raechelle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary","family":"Carroll","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincent","family":"Chung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.ctarc.2019.100155_bib0001","first-page":"7","article-title":"Cancer statistics, 2018","volume":"68","author":"Siegel","year":"2018","journal-title":"CA"},{"issue":"21","key":"10.1016\/j.ctarc.2019.100155_bib0002","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1056\/NEJM197111182852108","article-title":"Tumor angiogenesis: therapeutic implications","volume":"285","author":"Folkman","year":"1971","journal-title":"N. Engl. J. Med."},{"issue":"6","key":"10.1016\/j.ctarc.2019.100155_bib0003","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1002\/cncr.24149","article-title":"Role of surgical outcome as prognostic factor in advanced epithelial ovarian cancer: a combined exploratory analysis of 3 prospectively randomized phase 3 multicenter trials","volume":"115","author":"Du Bois","year":"2009","journal-title":"Cancer"},{"issue":"3","key":"10.1016\/j.ctarc.2019.100155_bib0004","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2165\/00003495-199958003-00001","article-title":"Oral alkylating agents for breast cancer therapy","volume":"58","author":"O'Shaughnessy","year":"1999","journal-title":"Drugs"},{"issue":"1","key":"10.1016\/j.ctarc.2019.100155_bib0005","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1056\/NEJM199601043340101","article-title":"Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer","volume":"334","author":"McGuire","year":"1996","journal-title":"N. Engl. J. Med."},{"issue":"9","key":"10.1016\/j.ctarc.2019.100155_bib0006","doi-asserted-by":"crossref","first-page":"3497","DOI":"10.1073\/pnas.91.9.3497","article-title":"Cell biological mechanisms of multidrug resistance in tumors","volume":"91","author":"Simon","year":"1994","journal-title":"Proc. Natl. Acad. Sci."},{"issue":"6754","key":"10.1016\/j.ctarc.2019.100155_bib0007","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1038\/44334","article-title":"Id1 and Id3 are required for neurogenesis, angiogenesis and vascularization of tumour xenografts.","volume":"401","author":"Lyden","year":"1999","journal-title":"Nature"},{"issue":"3","key":"10.1016\/j.ctarc.2019.100155_bib0008","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/S0092-8674(00)80108-7","article-title":"Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis","volume":"86","author":"Hanahan","year":"1996","journal-title":"Cell"},{"issue":"3","key":"10.1016\/j.ctarc.2019.100155_bib0009","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1093\/carcin\/21.3.505","article-title":"Tumor angiogenesis: past, present and the near future","volume":"21","author":"Kerbel","year":"2000","journal-title":"Carcinogenesis"},{"issue":"6","key":"10.1016\/j.ctarc.2019.100155_bib0010","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1016\/0092-8674(91)90033-U","article-title":"Neovascularization is associated with a switch to the export of bFGF in the multistep development of fibrosarcoma","volume":"66","author":"Kandel","year":"1991","journal-title":"Cell"},{"issue":"1","key":"10.1016\/j.ctarc.2019.100155_bib0011","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1146\/annurev.med.49.1.407","article-title":"Angiogenesis and tumor metastasis","volume":"49","author":"Zetter","year":"1998","journal-title":"Annu. Rev. Med."},{"issue":"23","key":"10.1016\/j.ctarc.2019.100155_bib0012","first-page":"5277","article-title":"Human angiostatin inhibits murine hemangioendothelioma tumor growth in vivo","volume":"57","author":"Lannutti","year":"1997","journal-title":"Cancer Res."},{"issue":"2","key":"10.1016\/j.ctarc.2019.100155_bib0013","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/S0092-8674(00)81848-6","article-title":"Endostatin: an endogenous inhibitor of angiogenesis and tumor growth","volume":"88","author":"O'Reilly","year":"1997","journal-title":"Cell"},{"key":"10.1016\/j.ctarc.2019.100155_bib0014","doi-asserted-by":"crossref","DOI":"10.3332\/ecancer.2017.723","article-title":"Clinical response in patients with ovarian cancer treated with metronomic chemotherapy","volume":"11","author":"Perroud","year":"2017","journal-title":"Ecancermedicalscience"},{"issue":"1\u20132","key":"10.1016\/j.ctarc.2019.100155_bib0015","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1159\/000320602","article-title":"Bevacizumab plus low-dose metronomic oral cyclophosphamide in heavily pretreated patients with recurrent ovarian cancer.","volume":"79","author":"S\u00e1nchez-Mu\u00f1oz","year":"2010","journal-title":"Oncology"},{"issue":"1","key":"10.1016\/j.ctarc.2019.100155_bib0016","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1186\/1471-2407-14-947","article-title":"Metronomic oral cyclophosphamide (MOC) in the salvage therapy of heavily treated recurrent ovarian cancer patients: a retrospective, multicenter study.","volume":"14","author":"Ferrandina","year":"2014","journal-title":"BMC Cancer"},{"issue":"5","key":"10.1016\/j.ctarc.2019.100155_bib0017","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1007\/s10147-010-0094-1","article-title":"Feasibility study of oral cyclophosphamide salvage therapy for the treatment of heavily pretreated patients with recurrent epithelial ovarian cancer","volume":"15","author":"Watanabe","year":"2010","journal-title":"Int. J. Clin. Oncol."},{"issue":"4","key":"10.1016\/j.ctarc.2019.100155_bib0018","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1016\/0016-5085(94)90246-1","article-title":"Up-regulation of cyclooxygenase 2 gene expression in human colorectal adenomas and adenocarcinomas","volume":"107","author":"Eberhart","year":"1994","journal-title":"Gastroenterology"},{"issue":"3","key":"10.1016\/j.ctarc.2019.100155_bib0019","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1002\/hep.510290355","article-title":"Expression of cyclooxygenase\u20102 in human hepatocellular carcinoma: relevance to tumor dedifferentiation","volume":"29","author":"Koga","year":"1999","journal-title":"Hepatology"},{"issue":"5","key":"10.1016\/j.ctarc.2019.100155_bib0020","first-page":"987","article-title":"Cyclooxygenase-2 expression is up-regulated in human pancreatic cancer","volume":"59","author":"Tucker","year":"1999","journal-title":"Cancer Res."},{"issue":"6","key":"10.1016\/j.ctarc.2019.100155_bib0021","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1093\/jnci\/90.6.455","article-title":"Expression of cyclooxygenase-1 and cyclooxygenase-2 in human breast cancer","volume":"90","author":"Hwang","year":"1998","journal-title":"JNCI"},{"issue":"17","key":"10.1016\/j.ctarc.2019.100155_bib0022","first-page":"3761","article-title":"Increased expression of cyclooxygenase 2 occurs frequently in human lung cancers, specifically in adenocarcinomas","volume":"58","author":"Hida","year":"1998","journal-title":"Cancer Res."},{"issue":"2","key":"10.1016\/j.ctarc.2019.100155_bib0023","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1007\/s10555-010-9223-6","article-title":"Interactions between lymphocytes and myeloid cells regulate pro-versus anti-tumor immunity","volume":"29","author":"DeNardo","year":"2010","journal-title":"Cancer Metastasis Rev."},{"issue":"5","key":"10.1016\/j.ctarc.2019.100155_bib0024","first-page":"1306","article-title":"Antiangiogenic and antitumor activities of cyclooxygenase-2 inhibitors","volume":"60","author":"Masferrer","year":"2000","journal-title":"Cancer Res."},{"issue":"1","key":"10.1016\/j.ctarc.2019.100155_bib0025","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1111\/j.1749-6632.1999.tb08726.x","article-title":"COX\u20102 Inhibitors: a new class of antiangiogenic agents","volume":"889","author":"Masferrer","year":"1999","journal-title":"Ann. N. Y. Acad. Sci."},{"issue":"1","key":"10.1016\/j.ctarc.2019.100155_bib0026","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1006\/jsre.1998.5511","article-title":"The effect of selective cyclooxygenase inhibitors on intestinal epithelial cell mitogenesis","volume":"81","author":"Erickson","year":"1999","journal-title":"J. Surg. Res."},{"issue":"2","key":"10.1016\/j.ctarc.2019.100155_bib0027","first-page":"362","article-title":"Modulation of apoptosis and Bcl-2 expression by prostaglandin E2 in human colon cancer cells","volume":"58","author":"Sheng","year":"1998","journal-title":"Cancer Res."},{"issue":"6","key":"10.1016\/j.ctarc.2019.100155_bib0028","doi-asserted-by":"crossref","first-page":"G1061","DOI":"10.1152\/ajpgi.1998.274.6.G1061","article-title":"Cyclooxygenase-2 inhibitors suppress the growth of gastric cancer xenografts via induction of apoptosis in nude mice","volume":"274","author":"Sawaoka","year":"1998","journal-title":"Am. J. Physiol.-Gastrointest. Liver Physiol."},{"issue":"19","key":"10.1016\/j.ctarc.2019.100155_bib0029","first-page":"4245","article-title":"NS398, a selective cyclooxygenase-2 inhibitor, induces apoptosis and down-regulates bcl-2 expression in LNCaP cells","volume":"58","author":"Liu","year":"1998","journal-title":"Cancer Res."},{"issue":"15","key":"10.1016\/j.ctarc.2019.100155_bib0030","doi-asserted-by":"crossref","first-page":"11397","DOI":"10.1074\/jbc.275.15.11397","article-title":"The cyclooxygenase-2 inhibitor celecoxib induces apoptosis by blocking akt activation in human prostate cancer cells independently of Bcl-2","volume":"275","author":"Hsu","year":"2000","journal-title":"J. Biol. Chem."},{"issue":"13","key":"10.1016\/j.ctarc.2019.100155_bib0031","doi-asserted-by":"crossref","first-page":"9102","DOI":"10.1074\/jbc.275.13.9102","article-title":"Angiopoietin-1 inhibits endothelial cell apoptosis via the Akt\/survivin pathway","volume":"275","author":"Papapetropoulos","year":"2000","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ctarc.2019.100155_bib0032","series-title":"Akt Takes Center Stage in Angiogenesis Signaling","author":"Dimmeler","year":"2000"},{"issue":"4","key":"10.1016\/j.ctarc.2019.100155_bib0033","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1073\/pnas.040560897","article-title":"Phosphatidylinositol 3-kinase signaling mediates angiogenesis and expression of vascular endothelial growth factor in endothelial cells","volume":"97","author":"Jiang","year":"2000","journal-title":"Proc. Natl. Acad. Sci."},{"issue":"2","key":"10.1016\/j.ctarc.2019.100155_bib0034","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1161\/01.ATV.20.2.402","article-title":"Insulin-mediated stimulation of protein kinase Akt: a potent survival signaling cascade for endothelial cells","volume":"20","author":"Hermann","year":"2000","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"issue":"2","key":"10.1016\/j.ctarc.2019.100155_bib0035","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1007\/BF00666043","article-title":"Potentiation of cytotoxic therapies by TNP-470 and minocycline in mice bearing EMT-6 mammary carcinoma","volume":"36","author":"Teicher","year":"1995","journal-title":"Breast Cancer Res. Treat."},{"issue":"19","key":"10.1016\/j.ctarc.2019.100155_bib0036","first-page":"5143","article-title":"Enhanced suppression of tumor growth by combination of angiogenesis inhibitor O-(chloroacetyl-carbamoyl) fumagillol (TNP-470) and cytotoxic agents in mice","volume":"54","author":"Kato","year":"1994","journal-title":"Cancer Res."},{"key":"10.1016\/j.ctarc.2019.100155_bib0037","doi-asserted-by":"crossref","DOI":"10.1097\/IGC.0000000000001258","article-title":"Angiogenesis inhibitors for the treatment of ovarian cancer: an updated systematic review and meta-analysis of randomized controlled trials.","author":"Wang","year":"2018","journal-title":"Int. J. Gynecol. Cancer"},{"issue":"3","key":"10.1016\/j.ctarc.2019.100155_bib0038","doi-asserted-by":"crossref","first-page":"451","DOI":"10.2217\/fon.12.196","article-title":"Safety and therapeutic effect of metronomic chemotherapy with cyclophosphamide and celecoxib in advanced breast cancer patients","volume":"9","author":"Perroud","year":"2013","journal-title":"Future Oncol."},{"issue":"1","key":"10.1016\/j.ctarc.2019.100155_bib0039","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/S1658-3876(10)50051-7","article-title":"A phase II study of high-dose celecoxib and metronomic'low-dose'cyclophosphamide and methotrexate in patients with relapsed and refractory lymphoma","volume":"3","author":"El Bary","year":"2010","journal-title":"Hematol. Oncol. Stem Cell Ther."},{"issue":"16_suppl","key":"10.1016\/j.ctarc.2019.100155_bib0040","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2005.23.16_suppl.3196","article-title":"Phase I trial of oral cyclophosphamide in combination with celecoxib in patients with advanced malignancies","volume":"23","author":"Twardowski","year":"2005","journal-title":"J. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.ctarc.2019.100155_bib0041","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/1757-2215-2-13","article-title":"Role of CA125 in predicting ovarian cancer survival-a review of the epidemiological literature","volume":"2","author":"Gupta","year":"2009","journal-title":"J. Ovarian Res."},{"key":"10.1016\/j.ctarc.2019.100155_bib0042","series-title":"2019 Annual Meeting of the Society of Gynecologic Cancer","article-title":"A phase II trial of pembrolizumab in combination with bevacizumab and oral metronomic cyclophosphamide for recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer","author":"Zsiros","year":"2019"}],"container-title":["Cancer Treatment and Research Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468294219300516?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468294219300516?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T06:17:42Z","timestamp":1762841862000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2468294219300516"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019]]},"references-count":42,"alternative-id":["S2468294219300516"],"URL":"https:\/\/doi.org\/10.1016\/j.ctarc.2019.100155","relation":{},"ISSN":["2468-2942"],"issn-type":[{"value":"2468-2942","type":"print"}],"subject":[],"published":{"date-parts":[[2019]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Randomized trial of oral cyclophosphamide versus oral cyclophosphamide with celecoxib for recurrent epithelial ovarian, fallopian tube, and primary peritoneal cancer","name":"articletitle","label":"Article Title"},{"value":"Cancer Treatment and Research Communications","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ctarc.2019.100155","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"100155"}}